Repare Therapeutics (NASDAQ:RPTX – Get Rating)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 155.10% from the stock’s current price.
Other equities analysts have also issued reports about the company. Morgan Stanley dropped their price target on Repare Therapeutics from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Monday, February 27th. Capital One Financial reissued an “overweight” rating and issued a $28.00 price target on shares of Repare Therapeutics in a research note on Friday, January 6th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Repare Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $24.25.
Repare Therapeutics Stock Performance
Shares of RPTX opened at $9.80 on Friday. Repare Therapeutics has a 52-week low of $8.06 and a 52-week high of $18.68. The business’s 50 day moving average price is $11.59 and its two-hundred day moving average price is $13.36. The firm has a market cap of $412.38 million, a PE ratio of -12.56 and a beta of 0.08.
Hedge Funds Weigh In On Repare Therapeutics
Repare Therapeutics Company Profile
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.